CONCENTRATIONS AND UNCERTAINTIES	12 Months Ended
Aug. 31, 2020
Risks and Uncertainties [Abstract]
CONCENTRATIONS AND UNCERTAINTIES	NOTE 10 – CONCENTRATIONS AND UNCERTAINTIES Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents and trade accounts receivable. The Company holds cash and cash equivalents at banks located in California, with balances that often exceed FDIC insured limits. Historically, the Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents. However, considering the current banking environment, the Company is investigating alternative ways to minimize its exposure to such risks. While the Company may be exposed to credit losses due to the nonperformance of its counterparties, the Company does not expect the settlement of these transactions to have a material effect on its results of operations, cash flows or financial condition. The Company maintains cash at financial institutions that may, at times, exceed federally insured limits. At August 31, 2020, the Company had cash and cash equivalents exceeding insured limits by $10,790,000. Revenue concentration shows that international sales accounted for 29%, 34% and 39% of net sales for fiscal years 2020, 2019 and 2018, respectively. Three customers accounted for 9%, 7% (a dealer account in Japan representing various customers), and 7% of net sales for fiscal year 2020. Three customers accounted for 8%, 8% (a dealer account in Japan representing various customers), and 7% of net sales for fiscal year 2019. Four customers accounted for 9% (a dealer account in Japan representing various customers), 7%, 6% and 5% of net sales for fiscal year 2018. FY20 accounts receivable concentrations show that two customers comprised 13% and 10% of accounts receivable as of August 31, 2020, respectively. FY19 accounts receivable concentrations show that one customer comprised 10% of accounts receivable as of August 31, 2019. We operate in the computer software industry, which is highly competitive and changes rapidly. Our operating results could be significantly affected by our ability to develop new products and find new distribution channels for new and existing products. The majority of our customers are in the pharmaceutical industry. During economic downturns, we have seen consolidations in the pharmaceutical industry. Although we have not seen any significant reduction in total revenues to date, our growth rate could be affected by consolidation and downsizing in the pharmaceutical industry.

CONCENTRATIONS AND UNCERTAINTIES

12 Months Ended

Aug. 31, 2020

NOTE 10 – CONCENTRATIONS AND UNCERTAINTIES

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents and trade accounts receivable. The Company holds cash and cash equivalents at banks located in California, with balances that often exceed FDIC insured limits. Historically, the Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents. However, considering the current banking environment, the Company is investigating alternative ways to minimize its exposure to such risks. While the Company may be exposed to credit losses due to the nonperformance of its counterparties, the Company does not expect the settlement of these transactions to have a material effect on its results of operations, cash flows or financial condition. The Company maintains cash at financial institutions that may, at times, exceed federally insured limits. At August 31, 2020, the Company had cash and cash equivalents exceeding insured limits by $10,790,000.

Revenue concentration shows that international sales accounted for 29%, 34% and 39% of net sales for fiscal years 2020, 2019 and 2018, respectively. Three customers accounted for 9%, 7% (a dealer account in Japan representing various customers), and 7% of net sales for fiscal year 2020. Three customers accounted for 8%, 8% (a dealer account in Japan representing various customers), and 7% of net sales for fiscal year 2019. Four customers accounted for 9% (a dealer account in Japan representing various customers), 7%, 6% and 5% of net sales for fiscal year 2018.

FY20 accounts receivable concentrations show that two customers comprised 13% and 10% of accounts receivable as of August 31, 2020, respectively. FY19 accounts receivable concentrations show that one customer comprised 10% of accounts receivable as of August 31, 2019.

We operate in the computer software industry, which is highly competitive and changes rapidly. Our operating results could be significantly affected by our ability to develop new products and find new distribution channels for new and existing products.

The majority of our customers are in the pharmaceutical industry. During economic downturns, we have seen consolidations in the pharmaceutical industry. Although we have not seen any significant reduction in total revenues to date, our growth rate could be affected by consolidation and downsizing in the pharmaceutical industry.